The report, titled “A Painful Pill to Swallow: U.S. vs. International Prescription Drug Prices,” compared drug prices in the U.S. to drug prices in the United Kingdom, Japan, Ontario, Australia, Portugal, France, the Netherlands, Germany, Denmark, Sweden and Switzerland.
It concluded that Americans pay significantly more than the other countries even when accounting for rebates, and that the U.S. could save $49 billion annually on Medicare Part D alone by pricing drugs similarly to the other countries studied. Most countries had average prices around 24 to 30 percent lower than those in the U.S.
The report illustrates why drugmakers are opposed to House Speaker Nancy Pelosi’s plan, which would allow the U.S. to negotiate drug prices by comparing them to other countries’ prices.
Read the full report here.
More articles on pharmacy:
Carcinogen concerns prompt Sandoz to halt global distribution of heartburn drug
DEA raids some West Coast Kaiser Permanente pharmacies
California biotech files for bankruptcy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.